CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21)

详细信息    查看全文

• 作者：Noriyoshi Iriyama ; Yoshihiro Hatta ; Jin Takeuchi ; Yoshiaki Ogawa ; Shigeki Ohtake ; Toru Sakura ; Kinuko Mitani ; Fumihiro Ishida ; Masatomo Takahashi ; Tomoya Maeda ; Tohru Izumi ; Hisashi Sakamaki ; Shuichi Miyawaki ; Sumihisa Honda ; Yasushi Miyazaki ; Tomohiko Taki ; Masafumi Taniwaki ; Tomoki Naoe
• 关键词：Acute myeloid leukemia with t(8 ; 21) ; CD56 antigen ; Prognostic factor
• 刊名：Leukemia Research
• 出版年：2013
• 出版时间：September, 2013
• 年：2013
• 卷：37
• 期：9
• 页码：1021-1026
• 全文大小：971 K

文摘

We investigated the significance of surface antigen expression for prognosis by focusing on a specific subtype, AML with t(8;21). The investigation included 144 patients with AML with t(8;21) in the JALSG AML97 study. AML with t(8;21) expressed CD19 (36 % ), CD34 (96 % ), and CD56 (65 % ) more frequently than did other subtypes of AML. CD19 expression had a significant favorable effect on CR (95.7 % vs. 83.8 % ; P = 0.049). Univariate analysis showed that increased white blood cell (WBC) counts (WBC ¡Ý 20 ¡Á 10⁹/L), CD19 negativity, and CD56 positivity were critical adverse factors for relapse after CR; multivariate analysis revealed that WBC count and CD56 expression were independent adverse risk factors (HR 2.18; P = 0.045, HR 2.30; P = 0.011, respectively). We concluded that CD56 expression has a possible role in risk stratification for patients with AML with t(8;21).